<DOC>
	<DOCNO>NCT00913614</DOCNO>
	<brief_summary>Given potential age-related difference safety , tolerability , pharmacokinetics , difference sleep architecture young child versus adolescent versus adult , study identify appropriate drug dosage child age essential address health problem impact child family . The objective study evaluate safety , pharmacokinetics preliminary efficacy eplivanserin . Primary objective : ass safety tolerability administration single ascend oral dos eplivanserin child age 6-17 year insomnia various origin . To assess pharmacokinetics eplivanserin ( active metabolite : SR141342 ) administration single ascend oral dos eplivanserin child age 6-17 year insomnia various origin . Secondary objective : assess effect single ascend oral dos eplivanserin global sleep parameter sleep architecture measure via polysomnography recording child age 6-17 year old insomnia various origin .</brief_summary>
	<brief_title>Single Dose Safety , Tolerability , Pharmacokinetic Pharmacodynamic Evaluation Eplivanserin Children With Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>SR 46349B</mesh_term>
	<criteria>Children diagnosis insomnia various origin . Complaint childhood insomnia define repeat difficulty sleep initiation consolidation occur despite adequate age appropriate time opportunity sleep . The existence sleep difficulty support statement child and/or caregiver sleep properly initiate maintain . Written consent must obtain parent/legal guardian . Written assent must obtain child appropriate age capable give assent determine parent/legal guardian . The sleep disturbance must attributable either direct physiologic effect drug abuse misuse prescribe medication . Subject , female childbearing potential , unwilling abstain sexual intercourse practice double contraception method length study . Mental retardation . The presence untreated uncompensated clinically significant renal , endocrine , hepatic , respiratory , cardiovascular , neurologic ( exclude ADHD ) , hematologic , immunologic , cerebrovascular disease , malignancy . Subjects history significant gastrointestinal disease . Presence drug alcohol abuse within one year inclusion . Current history substance abuse/dependence . Pregnant breastfeeding . Use hypnotics/psychotropics , antihistamine , melatonin , herbal product , sleep aid include clonidine initiation maintenance sleep within one week five half life ( whichever longer ) , prior screen unwillingness discontinue screen visit . Subject test positive screening baseline Day 1 , urine drug screen drug know alter sleep ( amphetamine/methamphetamines , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates alcohol ) . Inability swallow pill similar size tablet administer study . Current recent ( &lt; 60 day ) participation another clinical trial receive investigational drug . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>insomnia pediatric safety</keyword>
</DOC>